Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study

• Published in: Therapeutic advances in medical oncology 2024-01, Vol.16, p.17588359241229432-17588359241229432
• Main Authors: Okunaka, Mashiro, Kotani, Daisuke, Fujiwara, Hisashi, Sato, Kazuma, Fujiwara, Naoto, Mishima, Saori, Sakashita, Shingo, Yoshino, Takayuki, Fujita, Takeo, Kojima, Takashi
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Chemotherapy; Cisplatin; Clavicle; Cohort analysis; Esophageal cancer; Esophageal carcinoma; Lymph nodes; Lymphatic system; Medical prognosis; Metastases; Metastasis; Multivariate analysis; Original Research; Patients; Prognosis; Squamous cell carcinoma; Surgery
• ISSN: 1758-8359; 1758-8340; 1758-8359
• DOI: 10.1177/17588359241229432

Background: Docetaxel, cisplatin, and 5-fluorouracil (DCF) combination chemotherapy has been established as one of the standard neoadjuvant therapies for locally advanced esophageal squamous cell carcinoma (ESCC). However, little is known about prognostic factors in patients with residual pathological disease after neoadjuvant DCF followed by surgery for locally advanced ESCC who are candidates for adjuvant nivolumab. Objectives: This study aimed to investigate prognostic factors in patients with residual pathological disease after neoadjuvant DCF chemotherapy followed by surgery for locally advanced ESCC. Design: This was a retrospective cohort study. Methods: This retrospective cohort study included patients who received neoadjuvant DCF followed by surgery for locally advanced ESCC between June 2014 and January 2020 at the National Cancer Center Hospital East. Results: Among a total of 210 patients, 45 patients (21.4%) achieved a pathological complete response. The 3-year disease-free survival (DFS) rate was significantly lower in patients with residual pathological disease than in those with a pathological complete response [53.5% versus 74.5%; hazard ratio (HR): 2.09, 95% confidence interval (CI): 1.16–3.77, p = 0.01]. In patients with residual pathological disease (n = 165), multivariate analysis revealed that pathological node positivity (HR: 3.59, 95% CI: 1.92–6.71, p < 0.01), supraclavicular lymph node metastasis (HR: 2.15, 95% CI: 1.19–3.90, p = 0.01), and lymphovascular invasion (HR: 1.90, 95% CI: 1.14–3.17, p = 0.02) were significantly associated with poor DFS. Conclusion: In this largest-to-date cohort study, patients with residual pathological disease after neoadjuvant DCF followed by surgery for locally advanced ESCC had a poor prognosis. In these patients, pathological node positivity, including supraclavicular lymph node metastasis, and lymphovascular invasion were considered significant prognostic factors.